---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029901"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:03:30.679825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Axsome Therapeutics dismisses Ernst & Young, appoints Deloitte as auditor

## Summary
- Audit Committee approved dismissal of Ernst & Young and engagement of Deloitte & Touche for FY2023, effective June 30, 2023.
- Ernst & Young's reports on FY2021 and FY2022 financials were unqualified; no disagreements or reportable events.
- No consulting with Deloitte prior to engagement on accounting principles or audit matters.
- Ernst & Young furnished a letter agreeing with the disclosures, attached as Exhibit 16.1.

## SEC filing metadata
- accession: 0000950170-23-029901
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023029901/0000950170-23-029901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023029901/axsm-20230622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029901
- JSON: https://secwatch.observer/filing/0000950170-23-029901.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029901.txt

## Key facts
- Auditor Changes
  Axsome Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.
  - Action: dismissal
  - Auditor: Ernst & Young LLP
  - Successor: Deloitte & Touche LLP
  source text: On June 22, 2023, Ernst & Young LLP (“Ernst & Young”) was informed that the Committee approved Ernst & Young’s dismissal as the Company’s independent registered public accounting firm with such dismissal to be effective as of June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023029901/0000950170-23-029901-index.htm
- Auditor Changes
  Axsome Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.
  - Action: engagement
  - Auditor: Deloitte & Touche LLP
  source text: On June 22, 2023, the Audit Committee (the “Committee”) of the Board of Directors of Axsome Therapeutics, Inc. (“we,” “our,” “us,” or the “Company”) approved the engagement of Deloitte & Touche LLP (“Deloitte”), to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023 with such appointment to be effective as of June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023029901/0000950170-23-029901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.